Drug Profile
GBL 310
Latest Information Update: 12 Sep 2015
Price :
$50
*
At a glance
- Originator Grannus BioSciences
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Caspase 3 stimulants; MAP kinase kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Actinic keratosis
Most Recent Events
- 20 Feb 2007 Phase-II clinical trials in Actinic keratosis in United Kingdom (Topical)